Skip to main content

Table 4 List of clinical trials included for OS analysis

From: Agnostic evaluation of ipilimumab and nivolumab association: a metanalysis

Study No. patients Median OS (months) HR
CA209-067 [1, 2] n + i = 314
n = 316 		n + i = NR
n = 36.93 		HR 0.83
CA209-227 [4]
(OS PD-L1 > 1%) 		n + i = 396
n = 396 		n + i = 17.1
n = 15.7 		HR 0.79
Back to article page

Journal of Translational Medicine

ISSN: 1479-5876

Contact us